Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Vincent S. Shu"'
Publikováno v:
Anesthesiology. 97:565-573
Background The trend toward day-case surgery, with discharge on oral medication, has highlighted the need for effective and safe analgesics that facilitate a rapid recovery and discharge time. This study evaluated the analgesic efficacy, dose depende
Autor:
Steven C. Schachter, Kenneth W. Sommerville, Vincent S. Shu, William T Cahill, Braxton B. Wannamaker
Publikováno v:
Journal of Epilepsy. 11:248-255
This study was designed to determine the highest tiagabine dosage that could be administered as monotherapy to patients with complex partial seizures refractory to treatment with other antiepileptic drugs (AEDs) without unacceptable adverse events. T
Autor:
Vincent S. Shu, Kenneth W. Sommerville, Carl B. Dodrill, John L. Arnett, Glenn C. Pixton, Gregory T. Lenz
Publikováno v:
Epilepsia. 39:33-42
Summary: Purpose: We evaluated the dose-related impacts of tiagabine (TGB) on cognition and mood in a monotherapy study. Methods: Patients were 123 adults with uncontrolled partial seizures, each treated with a single currently available antiepilepti
Publikováno v:
The American Journal of Medicine. 88:S12-S17
The safety profile of estazolam, a new triazolobenzodiazepine hypnotic medication, has been developed in 1,320 normal volunteers and patients with insomnia. No clinically significant effects of estazolam on vital signs or laboratory values were detec
Autor:
Mark W. Pierce, Vincent S. Shu
Publikováno v:
The American Journal of Medicine. 88:S6-S11
The hypnotic efficacy of estazolam, a triazolobenzodiazepine, has been established in well-controlled sleep laboratory and outpatient clinical trials. Estazolam 1.0 mg and 2.0 mg significantly improves sleep latency, total sleep time, number of noctu
Autor:
Vincent S. Shu, Basim M. Uthman, Steven C. Schachter, Kenneth W. Sommerville, Peter A. Ahmann, A. James Rowan, Ilo E. Leppik
Publikováno v:
Archives of Neurology. 55:56
To determine the efficacy and tolerability of tiagabine, a new antiepileptic drug (AED) that inhibits gamma-aminobutyric acid (GABA) uptake, at 3 dose levels vs placebo as adjunctive therapy in patients with intractable complex partial seizures (CPS)
Autor:
Vincent S. Shu, Kenneth W. Sommerville, Gary L. Ringham, Ilo E. Leppik, Gregory L. Krauss, Robert F. Leroy, Rajesh C. Sachdeo, Philip M. Green, Miles E. Drake
Publikováno v:
Archives of Neurology. 54:595
Objective: To evaluate the efficacy and safety of 2 regimens of tiagabine as add-on therapy for patients with complex partial seizures (CPSs) that are refractory to other treatment. Design: Randomized, double-blind, placebocontrolled, add-on, paralle
Autor:
Vincent S. Shu, L. James Willmore
Publikováno v:
Neurology. 47:1356.3-1357
Reply from the Authors: Responding to Dr. Pledger's comments, the "intent-to-treat" results excluding only the three patients with no postrandomization efficacy data are shown below alongside the previously published results, which excluded seven add
Autor:
Robert J. Bielski, James M. Ferguson, Vincent S. Shu, Helene G. Pearlman, Gary L. Post, Roger Patrick, Mark W. Pierce, Lisa Bailey, John P. Houston, John E. Crowder
Publikováno v:
Journal of Clinical Psychopharmacology. 11:249
Estazolam, a triazolobenzodiazepine with an intermediate elimination half-life, has been shown previously to be an effective and safe hypnotic in insomniacs without concomitant psychiatric illness. Our study of the efficacy of estazolam in patients w
Autor:
Vincent S. Shu, Joseph R. Assenzo
Publikováno v:
Progress in neuro-psychopharmacologybiological psychiatry. 6(4-6)
1. Evaluation of the side effects of psychoactive drugs presents a special statistical situation because many of the symptoms of psychiatric disorders are also potential side effects. 2. Reported incidences of adverse events can be viewed as being a